NCT05225974View on ClinicalTrials.gov

A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 16, 2021

Primary Completion Date

July 30, 2021

Study Completion Date

August 19, 2021

Conditions
Therapeutic Equivalency
Interventions
DRUG

Liraglutide injection

At a single dose of 0.6 mg of Liraglutide injection by subcutaneous injection

DRUG

Liraglutide injection(Victoza®)

At a single dose of 0.6 mg of Liraglutide injection(Victoza®) by subcutaneous injection

Trial Locations (1)

266003

Phase I Clinical Research Center, Qingdao

All Listed Sponsors
lead

The Affiliated Hospital of Qingdao University

OTHER

NCT05225974 - A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects | Biotech Hunter | Biotech Hunter